Kadmon

$4.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-5.16%) Today
+$0.11 (+2.72%) As of 7:26 AM EST after-hours

Why Robinhood?

You can buy or sell Kadmon and other stocks, options, and ETFs commission-free!

About KDMN

Kadmon Holdings, Inc. Common Stock, also called Kadmon, is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. The listed name for KDMN is Kadmon Holdings, Inc. Common Stock.

CEO
Harlan W. Waksal
Employees
115
Headquarters
New York, New York
Founded
2010
Market Cap
692.91M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.24M
High Today
$4.31
Low Today
$3.92
Open Price
$4.24
Volume
3.25M
52 Week High
$5.50
52 Week Low
$2.30

Collections

KDMN Earnings

-$0.49
-$0.30
-$0.12
$0.07
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 4, After Hours

You May Also Like